IP Verse

Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients - EP3149480B1

PatentPatent Analysis

EP3149480

AMGEN
Application Number
EP15727072A
Filing Date
May 20, 2015
Status
Revoked
Sep 17, 2021
Grant Date
Dec 26, 2018
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3661562B1
EP3570885B1
EP4209499B1

Bibliography

The patent EP3149480B1 was granted to Amgen on Dec 26, 2018 following the initial filing on May 20, 2015 under the application number EP15727072A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFISep 26, 2019ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents